Zhouda Cai

Guangdong Key Laboratory Of Clinical Molecular Medicine And Diagnostics
Guangzhou, 510180, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer.

Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer.

Journal: Acta biochimica et biophysica Sinica

Published: January 13, 2026

Engineering endoplasmic reticulum targeted metal-polyphenol curcumin nanomicelles for melanoma therapy.

Engineering endoplasmic reticulum targeted metal-polyphenol curcumin nanomicelles for melanoma therapy.

Journal: Journal of nanobiotechnology

Published: October 06, 2025

Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target.

Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target.

Journal: Acta biochimica et biophysica Sinica

Published: August 28, 2025

Rare Cancer Explorer 1.0 (RaCE 1.0): a dedicated database and analytical platform focused on rare cancers.

Rare Cancer Explorer 1.0 (RaCE 1.0): a dedicated database and analytical platform focused on rare cancers.

Journal: Nucleic acids research

Published: June 26, 2025

S12micro: a machine learning-derived serum miRNA panel for high-performance pan-cancer diagnosis via liquid biopsy.

S12micro: a machine learning-derived serum miRNA panel for high-performance pan-cancer diagnosis via liquid biopsy.

Journal: International journal of surgery (London, England)

Published: June 19, 2025

Unveiling SMAD family member 6 as a novel biomarker for prognosis and immunotherapy response in testicular germ cell tumors.

Unveiling SMAD family member 6 as a novel biomarker for prognosis and immunotherapy response in testicular germ cell tumors.

Journal: Andrology

Published: November 14, 2024

Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells.

Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells.

Journal: Genetic testing and molecular biomarkers

Published: May 09, 2024

RNA modification Regulators' Co-Expression Score (RMRCoeS) predicts biochemical recurrence and therapy response in prostate cancer: A multi-omics and experimental validation study.

RNA modification Regulators' Co-Expression Score (RMRCoeS) predicts biochemical recurrence and therapy response in prostate cancer: A multi-omics and experimental validation study.

Journal: International immunopharmacology

Published: May 07, 2024

Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.

Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.

Journal: Cancer letters

Published: August 28, 2023

N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.

N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.

Journal: Human genetics

Published: May 26, 2023

A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.

A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.

Journal: Translational oncology

Published: January 25, 2023

Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.

Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.

Journal: Discover oncology

Published: January 16, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026